Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

UPDATE 2-Election polls thrust UK midcaps to 14-month high

Published 11/19/2019, 01:36 AM
Updated 11/19/2019, 01:36 AM
UPDATE 2-Election polls thrust UK midcaps to 14-month high

* FTSE 100 up 0.1%, FTSE 250 up 0.2%
* Aviva steepest decliner on main board
* Pound gains on election hopes
* IQE tanks after results warning
* Buyout offer spurs Consort Medical

(Adds news items, updates to closing prices)
By Muvija M and Shashwat Awasthi
Nov 18 (Reuters) - UK mid-caps closed at their highest level
in nearly 14 months on Monday, boosted by polls pointing to
victory by the ruling Conservatives in upcoming elections, while
a near 5% drop in insurer Aviva weighed on the main board.
The domestically-focused FTSE 250 index .FTMC rose 0.2%
while the FTSE 100 .FTSE added 0.1%.
A win by the opposition Labour Party "could cause turmoil on
the markets given the party wants to renationalise several
sectors and shake up taxes," Russ Mould, investment director at
AJ Bell, said.
"However, a lot can change in politics in three weeks so the
markets are likely to remain volatile right up to the big vote."

The bluechips ended higher after their worst weekly
performance in four despite a fall in oil majors, as investors
pooled their money into the so-called defensive stocks that are
perceived less risky at times of uncertainties.
Contradictory reports on Washington and Beijing's trade
dispute kept the market on edge. Chinese news agency Xinhua said
China and the United States had had "constructive talks", while
CNBC reported that U.S. President Donald Trump was reluctant to
roll back tariffs. Defensives from healthcare giant AstraZeneca AZN.L to
consumer goods company Reckitt Benckiser RB.L gained, despite
rises in the pound.
Aviva AV.L fell 4.6% to its lowest point since October
after the insurer said it would keep its operations in Singapore
and China amid speculation of a sale of the Singapore business.
"The fact that they have not been able to get a bid for it
or come to an agreement to sell it would lead you to believe
that they were unable to sell it so it isn't worth what they
think it is," a trader said.
Among smaller companies, IQE IQE.L plunged 23% after the
tech firm warned on results amid issues with two of its main
customers. Consort Medical CSRT.L sky-rocketed 44% past the
10.1 pound a share level on a bid from Sweden's Recipharm
RECIb.ST .
Biotechnology firm Puretech PRTC.L jumped 14% to top the
FTSE 250 index after its affiliate Karuna Therapeutics said its
experimental treatment for acute psychosis in schizophrenia met
key goals in a mid-stage trial.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.